I am reposting Jaybe's post re Spirit 3 trial in UK
From: jaybe
July update on Spirit 3 trial in UK...set to open in Q4...
Two arms: 500 patients each, randomized to either Imatinib or Nilotinib
Early switch: Poor responders (BCR-ABL>10%) switch to Ponatinib, otherwise stay on Imat/Nilo
Primary endpoint: Comparison of MMR at 3 years between Ponatinib, Nilotinib, and Imatinib
Secondary: Stop TKI therapy if MMR is maintained for 4 years
Looks like Pona dose will be 30mg, reduce to 15mg when MMR is maintained for 1 year
Presentation can be downloaded here:
spirit3.spirit-cml.org
